Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999603 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
A Phase 2 study of Viral Pneumonia, sponsored by Synairgen Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 550
- Enrollment target
- 20
- Study locations
NCT06999603: Recruiting Phase 2 study of Viral Pneumonia, sponsored by Synairgen Research.
NCT06999603 is a Phase 2 study of Viral Pneumonia that is actively recruiting participants, run by Synairgen Research. The registered enrollment target is 550 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (314% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999603, a Phase 2 study of Viral Pneumonia, is actively recruiting participants, sponsored by Synairgen Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 550 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this Phase 2 study is to assess about the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, compared with standard of care, will be studied. The study is split into two parts. All participants will receive standard of care in addition to SNG001 or placebo. In Part 1, the safety of SNG001 will be assessed. Participants of 50 years and older will receive study drug or placebo once a day for up to 14 days, whilst in hospital. In Part 2, the primary objective will be the efficacy of SNG001. Participants between 18 and 50 years with an immunocompromising condition and patients over 50 years (with or without an immunocompromising condition) will receive study drug once a day for up to 14 days, whilst in hospital.
Primary Outcome
The occurrence and severity of AEs and serious adverse events (SAEs), including pre-specified respiratory and cardiovascular deteriorations.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SNG001
Study Locations (20)
Ohio
- University of Cincinnati Medical Center (UCMC) - Cincinnati
- The Cleveland Clinic Foundation - Cleveland
- The Ohio State University (OSU) - Columbus
- Mercy St. Vincent Medical Center - Toledo
California
- University of California - Davis - Sacramento
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center - Torrance
Michigan
- Sinai-Grace Hospital - Detroit
- William Beaumont Hospital - Royal Oak
New York
- VA Western New York Healthcare system - Buffalo
- NYU Langone Tisch Hospital - New York
Florida
- NCH Pulmonary Critical Care - Naples
Georgia
- Emory University - Atlanta
Idaho
- Snake River Research, PLLC - Idaho Falls
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT06999603 shows while recruiting
NCT06999603 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (314% higher).
The record links to 1 condition, with Viral Pneumonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06999603 names 20 study sites across 14 states, led by Ohio, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06999603 about?
NCT06999603 is a clinical study titled "Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection". The goal of this Phase 2 study is to assess about the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, compared with standa...
What is the current status of trial NCT06999603?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 550 participants. The study started on 2025-09-02. Estimated completion is 2027-05.
What conditions does trial NCT06999603 study?
This clinical trial studies the following conditions: Viral Pneumonia.
What interventions are being tested in trial NCT06999603?
The interventions under investigation include: Placebo (DRUG), SNG001 (DRUG).
Who is sponsoring clinical trial NCT06999603?
This trial is sponsored by Synairgen Research, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999603 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06999603's enrollment target sits among peer trials
550 60th of 2000 higher than 1,940 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI